13G Filing: Granite Point Capital and Marinus Pharmaceuticals Inc (MRNS)

Page 10 of 13

Page 10 of 13 – SEC Filing

Item 4. OWNERSHIP
The information required by Items 4(a) – (c) is set forth in Rows 5-11 of the cover page for each Reporting Person and is incorporated herein by reference.
The percentages set forth in this Schedule 13G are calculated based on a total of 22,419,504 shares of Common Stock outstanding as of April 28, 2017, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2017 filed with the Securities and Exchange Commission on May 1, 2017.  
Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable.
Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable.
Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
Not applicable.
Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable.
Item 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
Item 10. CERTIFICATION
Each of the Reporting Persons hereby makes the following certification:
By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Follow Marinus Pharmaceuticals Inc. (NASDAQ:MRNS)

Page 10 of 13